[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yunlong Wang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100643817","the-combine-af-trial-100643817",false,"NCT07633509","The COMBINE-AF Trial","A Multicenter, Prospective, Randomized Controlled Trial of Combined Pulsed-Field and Radiofrequency-Modified Linear Ablation Versus Pulsed-Field Ablation Alone for Long-Standing Persistent Atrial Fibrillation","COMBINE-AF","Inclusion Criteria:\n\n* Symptomatic patients with long-standing persistent atrial fibrillation.\n* Duration of atrial fibrillation between 1 and 3 years.\n* Age 18 to 75 years.\n* Left atrial diameter between 43 mm and 55 mm.\n* Documentation of atrial fibrillation within 3 years prior to enrollment.\n* Willing and able to comply with the study protocol and provide written informed consent.\n\nExclusion Criteria:\n\n* Paroxysmal atrial fibrillation, or evidence of sinus rhythm on electrocardiogram within the past year.\n* Persistent atrial fibrillation lasting less than 1 year or more than 3 years.\n* Left atrial thrombus.\n* Prior catheter ablation for atrial fibrillation.\n* Coexisting severe organic heart disease (e.g., severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.).\n* Left atrial diameter (LAD) \\>55 mm.\n* Left ventricular ejection fraction (LVEF) \\\u003C40%.\n* Known allergy or contraindication to low-molecular-weight heparin, warfarin, or direct oral anticoagulants.\n* Undergoing a \"one-stop\" procedure combining atrial fibrillation ablation with left atrial appendage closure.\n* Allergy to alcohol or contrast media.\n* Pulmonary artery systolic pressure \\>50 mmHg.\n* Unstable angina pectoris.\n* Percutaneous coronary intervention (PCI) within the past 3 months.\n* Cardiac surgery within the past 6 months.\n* Planned heart transplantation.\n* History of thromboembolic disease within the past 6 months (including venous thromboembolism: pulmonary embolism, deep vein thrombosis; or arterial thromboembolic disease: acute coronary syndrome, lower extremity arterial embolism, stroke).\n* Left atrial myxoma.\n* Severe respiratory disease.\n* Active infectious disease.\n* Poorly controlled or active systemic immune disease (equivalent to glucocorticoid use \\>2 tablets\u002Fday).\n* Unresolved malignant hematologic disease, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Unresolved malignant solid tumor, or currently receiving chemotherapy, radiotherapy, or immunotherapy.\n* Untreated hypothyroidism or hyperthyroidism.\n* Severe hepatic insufficiency (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>3 times the upper limit of normal).\n* End-stage renal failure requiring dialysis.\n* Other serious arrhythmias, such as hemodynamically unstable ventricular tachycardia.\n* Pregnancy or breast-feeding.\n* Psychiatric disorder.\n* Body mass index (BMI) \\\u003C18.5 or \\>35.0 kg\u002Fm².\n* Life expectancy \\\u003C2 years.","ALL","18 Years","75 Years",{"count":21,"type":22},430,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to test if a more complete ablation procedure works better than the standard procedure for people with long-lasting atrial fibrillation (AF). AF is a heart rhythm problem that can cause a fast or uneven heartbeat.\n\nThis study will include 430 people with long-lasting AF that has lasted 1 to 3 years. Participants will be put into one of two groups by chance:\n\nFirst group (control): They will receive pulsed-field ablation (PFA), a type of energy that can stop the faulty heart signals. They will have isolation of the pulmonary veins and the back wall of the left atrium.\n\nSecond group (study): They will receive the same PFA procedure plus extra ablation lines (modified linear ablation) using radiofrequency energy. This includes ablation of the mitral isthmus (with ethanol infusion into a small vein called the vein of Marshall) and the cavotricuspid isthmus.\n\nParticipants will be followed for 12 months after the procedure with clinic visits, electrocardiograms (ECGs), and heart rhythm monitors. The main outcome is whether participants stay in normal heart rhythm (sinus rhythm) without any AF episodes lasting more than 30 seconds at 12 months. Researchers will also look at procedure time, complication rates, quality of life, and other rhythm outcomes.\n\nThis study will help show if the more complete ablation procedure leads to better long-term results for people with long-lasting AF.",[28,29],"Atrial Fibrillation (AF)","Atrial Fibrillation Catheter Ablation",[31,32,33,34,35],"Atrial Fibrillation","Catheter Ablation","Long-standing Persistent Atrial Fibrillation","Pulsed Field Ablation","Radiofrequency Ablation","NOT_YET_RECRUITING","2026-06-04",{"date":39,"type":40},"2026-06-08","ACTUAL",{"date":42,"type":22},"2026-06-15",{"date":44,"type":22},"2029-12-31",{"name":46,"class":47},"Yunlong Wang","OTHER",3,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100639226","phase-4-tirzepatide-on-atrial-fibrillation-recurrence-after-catheter-ablation-in-patients-with-obesity-and-hfpef-100639226","NCT07630454","Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF","Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Obese and HFpEF: A Randomized Controlled Trial","TEAR-AF-HFpEF","Inclusion Criteria:\n\n* Age 18 to 80 years\n* Symptomatic atrial fibrillation (paroxysmal or persistent of ≤ 5 years duration), undergoing first-time catheter ablation\n* Body weight criteria (aligned with NMPA-approved tirzepatide indication)，meeting at least one of the following:\n\n  * BMI ≥28.0 kg\u002Fm² (obesity threshold per Chinese criteria), OR\n  * BMI ≥24.0 kg\u002Fm² and \\\u003C28.0 kg\u002Fm² (overweight per Chinese criteria) with at least one weight-related comorbidity: hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM), obstructive sleep apnea syndrome (OSAS), or atherosclerotic cardiovascular disease (ASCVD)\n* HFpEF defined by intraprocedural mean left atrial pressure ≥ 15 mmHg at rest\n* Left ventricular ejection fraction ≥ 50% on echocardiography within 30 days prior to enrollment\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Prior use of any GLP-1 receptor agonist or GIP\u002FGLP-1 dual receptor agonist\n* Type 1 diabetes mellitus; or type 2 diabetes with HbA1c \\> 10%\n* Personal history of pancreatitis; personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n* Severe gastrointestinal disease, including gastroparesis or active inflammatory bowel disease\n* Prior bariatric surgery\n* Moderate or severe valvular heart disease, hypertrophic cardiomyopathy, cardiac amyloidosis, constrictive pericarditis, or restrictive cardiomyopathy\n* Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Active malignancy, excluding basal cell carcinoma\n* Acute coronary syndrome, stroke, percutaneous coronary intervention, or cardiac surgery within 30 days prior to enrollment\n* Pregnancy, lactation, or planned pregnancy within 6 months\n* Life expectancy \\\u003C 12 months\n* Concurrent participation in another interventional clinical trial\n* Any condition that, in the investigator's judgment, would interfere with participation","80 Years",{"count":59,"type":22},602,[61],"PHASE4","This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart failure with preserved ejection fraction (HFpEF). HFpEF is diagnosed by direct intraprocedural measurement of mean left atrial pressure (mLAP ≥ 15 mmHg at rest) during the ablation procedure, providing a hemodynamically anchored, homogeneous study population free from the diagnostic ambiguities of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and E\u002Fe' in AF patients. Approximately 602 participants will be randomized 1:1 to tirzepatide (titrated to a target of 10 mg\u002Fweek, maximum 15 mg\u002Fweek) plus standard care, or standard care alone. Both groups receive an identical structured lifestyle intervention. The primary endpoint is the first documented AF\u002Fatrial flutter\u002Fatrial tachycardia episode lasting ≥ 30 seconds, occurring between day 91 and day 365 after ablation, adjudicated by an independent blinded clinical endpoint committee.",[31,64,65],"Heart Failure With Preserved Ejection Fraction (HFpEF)","Tirzepatide",[31,65,67,68,69],"GIP\u002FGLP-1 receptor agonist","Obesity","HFpEF","2026-06-03",{"date":72,"type":40},"2026-06-05",{"date":74,"type":22},"2026-08-01",{"date":76,"type":22},"2029-12-01",{"name":46,"class":47},1,""]